EClinicalMedicine-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=964326, encodeId=3f44964326fb, content=EClinicalMedicine has been accepted to the Science Citation Index Expanded and expects its first Journal Impact Factor in 2022. 这是该杂志官方首页上写的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=22e82567, createdName=dangjunsy, createdTime=Mon May 10 18:17:41 CST 2021, time=2021-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2157837, encodeId=5318215e8377a, content=2, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93bb8315605, createdName=ms1000000667415119, createdTime=Fri Sep 15 14:42:32 CST 2023, time=2023-09-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=580620, encodeId=2dd658062063, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：这个杂志是柳叶刀旗下的，与EBioMedicine对应，临床类各科文章皆收录，属于大而全的，所以取名为EClinicalMedicine，定位应该是承接被Lancet主刊和子刊退稿或拒稿的文章。未来应该与EBioMedicine差不多，在5分左右。就象Nature旗下的Nature Communication和Sci Rep一样，综合类期刊。不过，相对而言文章更好发表哦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=619, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Thu Nov 28 12:06:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205559, encodeId=1f75120555959, content=有同行如果有web of science的access可以精确预估一下今年的影响因子，2019+2020文章在2021年的引用次数/2019+2020文章数量，网站上的累计引用不准确, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=499, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66412075254, createdName=1881f0fc47m, createdTime=Thu Mar 24 13:43:20 CST 2022, time=2022-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201089, encodeId=8d88120108906, content=为什么最近的很多帖子都被删掉了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=355, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=22e82567, createdName=dangjunsy, createdTime=Wed Mar 09 23:10:55 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113162, encodeId=d05a11131628f, content=撰写文章题目有没有技巧？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:55 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113161, encodeId=14ea1113161e8, content=文章题目怎么写更好？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:55 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2200038, encodeId=9fea22000387d, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc86161054, createdName=ms3000001089264574, createdTime=Tue Apr 23 22:07:09 CST 2024, time=2024-04-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2195328, encodeId=27262195328a4, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：无投稿经验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=daa79231007, createdName=ms3000001661232973, createdTime=Mon Mar 25 21:56:28 CST 2024, time=2024-03-25, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2187957, encodeId=9517218e95705, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤 经验分享：编辑很nice，也很细心, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de166462153, createdName=ms9000001999156742, createdTime=Sun Feb 18 14:05:11 CST 2024, time=2024-02-18, status=1, ipAttribution=上海)]

2021-05-10 dangjunsy

EClinicalMedicine has been accepted to the Science Citation Index Expanded and expects its first Journal Impact Factor in 2022.
这是该杂志官方首页上写的

80 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=964326, encodeId=3f44964326fb, content=EClinicalMedicine has been accepted to the Science Citation Index Expanded and expects its first Journal Impact Factor in 2022. 这是该杂志官方首页上写的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=22e82567, createdName=dangjunsy, createdTime=Mon May 10 18:17:41 CST 2021, time=2021-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2157837, encodeId=5318215e8377a, content=2, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93bb8315605, createdName=ms1000000667415119, createdTime=Fri Sep 15 14:42:32 CST 2023, time=2023-09-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=580620, encodeId=2dd658062063, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：这个杂志是柳叶刀旗下的，与EBioMedicine对应，临床类各科文章皆收录，属于大而全的，所以取名为EClinicalMedicine，定位应该是承接被Lancet主刊和子刊退稿或拒稿的文章。未来应该与EBioMedicine差不多，在5分左右。就象Nature旗下的Nature Communication和Sci Rep一样，综合类期刊。不过，相对而言文章更好发表哦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=619, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Thu Nov 28 12:06:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205559, encodeId=1f75120555959, content=有同行如果有web of science的access可以精确预估一下今年的影响因子，2019+2020文章在2021年的引用次数/2019+2020文章数量，网站上的累计引用不准确, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=499, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66412075254, createdName=1881f0fc47m, createdTime=Thu Mar 24 13:43:20 CST 2022, time=2022-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201089, encodeId=8d88120108906, content=为什么最近的很多帖子都被删掉了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=355, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=22e82567, createdName=dangjunsy, createdTime=Wed Mar 09 23:10:55 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113162, encodeId=d05a11131628f, content=撰写文章题目有没有技巧？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:55 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113161, encodeId=14ea1113161e8, content=文章题目怎么写更好？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:55 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2200038, encodeId=9fea22000387d, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc86161054, createdName=ms3000001089264574, createdTime=Tue Apr 23 22:07:09 CST 2024, time=2024-04-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2195328, encodeId=27262195328a4, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：无投稿经验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=daa79231007, createdName=ms3000001661232973, createdTime=Mon Mar 25 21:56:28 CST 2024, time=2024-03-25, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2187957, encodeId=9517218e95705, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤 经验分享：编辑很nice，也很细心, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de166462153, createdName=ms9000001999156742, createdTime=Sun Feb 18 14:05:11 CST 2024, time=2024-02-18, status=1, ipAttribution=上海)]

2023-09-15 ms1000000667415119 来自北京

2

81 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=964326, encodeId=3f44964326fb, content=EClinicalMedicine has been accepted to the Science Citation Index Expanded and expects its first Journal Impact Factor in 2022. 这是该杂志官方首页上写的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=22e82567, createdName=dangjunsy, createdTime=Mon May 10 18:17:41 CST 2021, time=2021-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2157837, encodeId=5318215e8377a, content=2, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93bb8315605, createdName=ms1000000667415119, createdTime=Fri Sep 15 14:42:32 CST 2023, time=2023-09-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=580620, encodeId=2dd658062063, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：这个杂志是柳叶刀旗下的，与EBioMedicine对应，临床类各科文章皆收录，属于大而全的，所以取名为EClinicalMedicine，定位应该是承接被Lancet主刊和子刊退稿或拒稿的文章。未来应该与EBioMedicine差不多，在5分左右。就象Nature旗下的Nature Communication和Sci Rep一样，综合类期刊。不过，相对而言文章更好发表哦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=619, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Thu Nov 28 12:06:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205559, encodeId=1f75120555959, content=有同行如果有web of science的access可以精确预估一下今年的影响因子，2019+2020文章在2021年的引用次数/2019+2020文章数量，网站上的累计引用不准确, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=499, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66412075254, createdName=1881f0fc47m, createdTime=Thu Mar 24 13:43:20 CST 2022, time=2022-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201089, encodeId=8d88120108906, content=为什么最近的很多帖子都被删掉了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=355, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=22e82567, createdName=dangjunsy, createdTime=Wed Mar 09 23:10:55 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113162, encodeId=d05a11131628f, content=撰写文章题目有没有技巧？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:55 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113161, encodeId=14ea1113161e8, content=文章题目怎么写更好？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:55 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2200038, encodeId=9fea22000387d, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc86161054, createdName=ms3000001089264574, createdTime=Tue Apr 23 22:07:09 CST 2024, time=2024-04-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2195328, encodeId=27262195328a4, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：无投稿经验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=daa79231007, createdName=ms3000001661232973, createdTime=Mon Mar 25 21:56:28 CST 2024, time=2024-03-25, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2187957, encodeId=9517218e95705, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤 经验分享：编辑很nice，也很细心, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de166462153, createdName=ms9000001999156742, createdTime=Sun Feb 18 14:05:11 CST 2024, time=2024-02-18, status=1, ipAttribution=上海)]

2019-11-28 lovetcm

审稿速度:2.0 | 投稿命中率:75.0
经验分享：这个杂志是柳叶刀旗下的，与EBioMedicine对应，临床类各科文章皆收录，属于大而全的，所以取名为EClinicalMedicine，定位应该是承接被Lancet主刊和子刊退稿或拒稿的文章。未来应该与EBioMedicine差不多，在5分左右。就象Nature旗下的Nature Communication和Sci Rep一样，综合类期刊。不过，相对而言文章更好发表哦

619 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=964326, encodeId=3f44964326fb, content=EClinicalMedicine has been accepted to the Science Citation Index Expanded and expects its first Journal Impact Factor in 2022. 这是该杂志官方首页上写的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=22e82567, createdName=dangjunsy, createdTime=Mon May 10 18:17:41 CST 2021, time=2021-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2157837, encodeId=5318215e8377a, content=2, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93bb8315605, createdName=ms1000000667415119, createdTime=Fri Sep 15 14:42:32 CST 2023, time=2023-09-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=580620, encodeId=2dd658062063, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：这个杂志是柳叶刀旗下的，与EBioMedicine对应，临床类各科文章皆收录，属于大而全的，所以取名为EClinicalMedicine，定位应该是承接被Lancet主刊和子刊退稿或拒稿的文章。未来应该与EBioMedicine差不多，在5分左右。就象Nature旗下的Nature Communication和Sci Rep一样，综合类期刊。不过，相对而言文章更好发表哦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=619, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Thu Nov 28 12:06:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205559, encodeId=1f75120555959, content=有同行如果有web of science的access可以精确预估一下今年的影响因子，2019+2020文章在2021年的引用次数/2019+2020文章数量，网站上的累计引用不准确, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=499, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66412075254, createdName=1881f0fc47m, createdTime=Thu Mar 24 13:43:20 CST 2022, time=2022-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201089, encodeId=8d88120108906, content=为什么最近的很多帖子都被删掉了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=355, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=22e82567, createdName=dangjunsy, createdTime=Wed Mar 09 23:10:55 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113162, encodeId=d05a11131628f, content=撰写文章题目有没有技巧？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:55 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113161, encodeId=14ea1113161e8, content=文章题目怎么写更好？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:55 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2200038, encodeId=9fea22000387d, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc86161054, createdName=ms3000001089264574, createdTime=Tue Apr 23 22:07:09 CST 2024, time=2024-04-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2195328, encodeId=27262195328a4, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：无投稿经验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=daa79231007, createdName=ms3000001661232973, createdTime=Mon Mar 25 21:56:28 CST 2024, time=2024-03-25, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2187957, encodeId=9517218e95705, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤 经验分享：编辑很nice，也很细心, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de166462153, createdName=ms9000001999156742, createdTime=Sun Feb 18 14:05:11 CST 2024, time=2024-02-18, status=1, ipAttribution=上海)]

2022-03-24 1881f0fc47m

有同行如果有web of science的access可以精确预估一下今年的影响因子，2019+2020文章在2021年的引用次数/2019+2020文章数量，网站上的累计引用不准确

499 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=964326, encodeId=3f44964326fb, content=EClinicalMedicine has been accepted to the Science Citation Index Expanded and expects its first Journal Impact Factor in 2022. 这是该杂志官方首页上写的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=22e82567, createdName=dangjunsy, createdTime=Mon May 10 18:17:41 CST 2021, time=2021-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2157837, encodeId=5318215e8377a, content=2, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93bb8315605, createdName=ms1000000667415119, createdTime=Fri Sep 15 14:42:32 CST 2023, time=2023-09-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=580620, encodeId=2dd658062063, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：这个杂志是柳叶刀旗下的，与EBioMedicine对应，临床类各科文章皆收录，属于大而全的，所以取名为EClinicalMedicine，定位应该是承接被Lancet主刊和子刊退稿或拒稿的文章。未来应该与EBioMedicine差不多，在5分左右。就象Nature旗下的Nature Communication和Sci Rep一样，综合类期刊。不过，相对而言文章更好发表哦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=619, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Thu Nov 28 12:06:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205559, encodeId=1f75120555959, content=有同行如果有web of science的access可以精确预估一下今年的影响因子，2019+2020文章在2021年的引用次数/2019+2020文章数量，网站上的累计引用不准确, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=499, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66412075254, createdName=1881f0fc47m, createdTime=Thu Mar 24 13:43:20 CST 2022, time=2022-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201089, encodeId=8d88120108906, content=为什么最近的很多帖子都被删掉了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=355, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=22e82567, createdName=dangjunsy, createdTime=Wed Mar 09 23:10:55 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113162, encodeId=d05a11131628f, content=撰写文章题目有没有技巧？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:55 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113161, encodeId=14ea1113161e8, content=文章题目怎么写更好？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:55 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2200038, encodeId=9fea22000387d, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc86161054, createdName=ms3000001089264574, createdTime=Tue Apr 23 22:07:09 CST 2024, time=2024-04-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2195328, encodeId=27262195328a4, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：无投稿经验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=daa79231007, createdName=ms3000001661232973, createdTime=Mon Mar 25 21:56:28 CST 2024, time=2024-03-25, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2187957, encodeId=9517218e95705, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤 经验分享：编辑很nice，也很细心, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de166462153, createdName=ms9000001999156742, createdTime=Sun Feb 18 14:05:11 CST 2024, time=2024-02-18, status=1, ipAttribution=上海)]

2022-03-09 dangjunsy

为什么最近的很多帖子都被删掉了？

355 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=964326, encodeId=3f44964326fb, content=EClinicalMedicine has been accepted to the Science Citation Index Expanded and expects its first Journal Impact Factor in 2022. 这是该杂志官方首页上写的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=22e82567, createdName=dangjunsy, createdTime=Mon May 10 18:17:41 CST 2021, time=2021-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2157837, encodeId=5318215e8377a, content=2, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93bb8315605, createdName=ms1000000667415119, createdTime=Fri Sep 15 14:42:32 CST 2023, time=2023-09-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=580620, encodeId=2dd658062063, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：这个杂志是柳叶刀旗下的，与EBioMedicine对应，临床类各科文章皆收录，属于大而全的，所以取名为EClinicalMedicine，定位应该是承接被Lancet主刊和子刊退稿或拒稿的文章。未来应该与EBioMedicine差不多，在5分左右。就象Nature旗下的Nature Communication和Sci Rep一样，综合类期刊。不过，相对而言文章更好发表哦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=619, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Thu Nov 28 12:06:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205559, encodeId=1f75120555959, content=有同行如果有web of science的access可以精确预估一下今年的影响因子，2019+2020文章在2021年的引用次数/2019+2020文章数量，网站上的累计引用不准确, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=499, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66412075254, createdName=1881f0fc47m, createdTime=Thu Mar 24 13:43:20 CST 2022, time=2022-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201089, encodeId=8d88120108906, content=为什么最近的很多帖子都被删掉了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=355, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=22e82567, createdName=dangjunsy, createdTime=Wed Mar 09 23:10:55 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113162, encodeId=d05a11131628f, content=撰写文章题目有没有技巧？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:55 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113161, encodeId=14ea1113161e8, content=文章题目怎么写更好？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:55 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2200038, encodeId=9fea22000387d, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc86161054, createdName=ms3000001089264574, createdTime=Tue Apr 23 22:07:09 CST 2024, time=2024-04-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2195328, encodeId=27262195328a4, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：无投稿经验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=daa79231007, createdName=ms3000001661232973, createdTime=Mon Mar 25 21:56:28 CST 2024, time=2024-03-25, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2187957, encodeId=9517218e95705, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤 经验分享：编辑很nice，也很细心, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de166462153, createdName=ms9000001999156742, createdTime=Sun Feb 18 14:05:11 CST 2024, time=2024-02-18, status=1, ipAttribution=上海)]

2021-12-29 桑晒麦拉

撰写文章题目有没有技巧？

149 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=964326, encodeId=3f44964326fb, content=EClinicalMedicine has been accepted to the Science Citation Index Expanded and expects its first Journal Impact Factor in 2022. 这是该杂志官方首页上写的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=22e82567, createdName=dangjunsy, createdTime=Mon May 10 18:17:41 CST 2021, time=2021-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2157837, encodeId=5318215e8377a, content=2, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93bb8315605, createdName=ms1000000667415119, createdTime=Fri Sep 15 14:42:32 CST 2023, time=2023-09-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=580620, encodeId=2dd658062063, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：这个杂志是柳叶刀旗下的，与EBioMedicine对应，临床类各科文章皆收录，属于大而全的，所以取名为EClinicalMedicine，定位应该是承接被Lancet主刊和子刊退稿或拒稿的文章。未来应该与EBioMedicine差不多，在5分左右。就象Nature旗下的Nature Communication和Sci Rep一样，综合类期刊。不过，相对而言文章更好发表哦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=619, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Thu Nov 28 12:06:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205559, encodeId=1f75120555959, content=有同行如果有web of science的access可以精确预估一下今年的影响因子，2019+2020文章在2021年的引用次数/2019+2020文章数量，网站上的累计引用不准确, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=499, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66412075254, createdName=1881f0fc47m, createdTime=Thu Mar 24 13:43:20 CST 2022, time=2022-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201089, encodeId=8d88120108906, content=为什么最近的很多帖子都被删掉了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=355, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=22e82567, createdName=dangjunsy, createdTime=Wed Mar 09 23:10:55 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113162, encodeId=d05a11131628f, content=撰写文章题目有没有技巧？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:55 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113161, encodeId=14ea1113161e8, content=文章题目怎么写更好？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:55 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2200038, encodeId=9fea22000387d, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc86161054, createdName=ms3000001089264574, createdTime=Tue Apr 23 22:07:09 CST 2024, time=2024-04-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2195328, encodeId=27262195328a4, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：无投稿经验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=daa79231007, createdName=ms3000001661232973, createdTime=Mon Mar 25 21:56:28 CST 2024, time=2024-03-25, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2187957, encodeId=9517218e95705, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤 经验分享：编辑很nice，也很细心, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de166462153, createdName=ms9000001999156742, createdTime=Sun Feb 18 14:05:11 CST 2024, time=2024-02-18, status=1, ipAttribution=上海)]

2021-12-28 ms6000000264964247

文章题目怎么写更好？

100 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=964326, encodeId=3f44964326fb, content=EClinicalMedicine has been accepted to the Science Citation Index Expanded and expects its first Journal Impact Factor in 2022. 这是该杂志官方首页上写的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=22e82567, createdName=dangjunsy, createdTime=Mon May 10 18:17:41 CST 2021, time=2021-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2157837, encodeId=5318215e8377a, content=2, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93bb8315605, createdName=ms1000000667415119, createdTime=Fri Sep 15 14:42:32 CST 2023, time=2023-09-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=580620, encodeId=2dd658062063, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：这个杂志是柳叶刀旗下的，与EBioMedicine对应，临床类各科文章皆收录，属于大而全的，所以取名为EClinicalMedicine，定位应该是承接被Lancet主刊和子刊退稿或拒稿的文章。未来应该与EBioMedicine差不多，在5分左右。就象Nature旗下的Nature Communication和Sci Rep一样，综合类期刊。不过，相对而言文章更好发表哦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=619, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Thu Nov 28 12:06:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205559, encodeId=1f75120555959, content=有同行如果有web of science的access可以精确预估一下今年的影响因子，2019+2020文章在2021年的引用次数/2019+2020文章数量，网站上的累计引用不准确, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=499, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66412075254, createdName=1881f0fc47m, createdTime=Thu Mar 24 13:43:20 CST 2022, time=2022-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201089, encodeId=8d88120108906, content=为什么最近的很多帖子都被删掉了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=355, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=22e82567, createdName=dangjunsy, createdTime=Wed Mar 09 23:10:55 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113162, encodeId=d05a11131628f, content=撰写文章题目有没有技巧？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:55 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113161, encodeId=14ea1113161e8, content=文章题目怎么写更好？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:55 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2200038, encodeId=9fea22000387d, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc86161054, createdName=ms3000001089264574, createdTime=Tue Apr 23 22:07:09 CST 2024, time=2024-04-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2195328, encodeId=27262195328a4, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：无投稿经验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=daa79231007, createdName=ms3000001661232973, createdTime=Mon Mar 25 21:56:28 CST 2024, time=2024-03-25, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2187957, encodeId=9517218e95705, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤 经验分享：编辑很nice，也很细心, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de166462153, createdName=ms9000001999156742, createdTime=Sun Feb 18 14:05:11 CST 2024, time=2024-02-18, status=1, ipAttribution=上海)]

2024-04-23 ms3000001089264574 来自广东省

审稿速度:2.0 | 投稿命中率:75.0
偏重的研究方向：肿瘤
经验分享：好

3 0

[GetPortalCommentsPageByObjectIdResponse(id=964326, encodeId=3f44964326fb, content=EClinicalMedicine has been accepted to the Science Citation Index Expanded and expects its first Journal Impact Factor in 2022. 这是该杂志官方首页上写的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=22e82567, createdName=dangjunsy, createdTime=Mon May 10 18:17:41 CST 2021, time=2021-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2157837, encodeId=5318215e8377a, content=2, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93bb8315605, createdName=ms1000000667415119, createdTime=Fri Sep 15 14:42:32 CST 2023, time=2023-09-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=580620, encodeId=2dd658062063, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：这个杂志是柳叶刀旗下的，与EBioMedicine对应，临床类各科文章皆收录，属于大而全的，所以取名为EClinicalMedicine，定位应该是承接被Lancet主刊和子刊退稿或拒稿的文章。未来应该与EBioMedicine差不多，在5分左右。就象Nature旗下的Nature Communication和Sci Rep一样，综合类期刊。不过，相对而言文章更好发表哦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=619, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Thu Nov 28 12:06:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205559, encodeId=1f75120555959, content=有同行如果有web of science的access可以精确预估一下今年的影响因子，2019+2020文章在2021年的引用次数/2019+2020文章数量，网站上的累计引用不准确, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=499, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66412075254, createdName=1881f0fc47m, createdTime=Thu Mar 24 13:43:20 CST 2022, time=2022-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201089, encodeId=8d88120108906, content=为什么最近的很多帖子都被删掉了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=355, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=22e82567, createdName=dangjunsy, createdTime=Wed Mar 09 23:10:55 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113162, encodeId=d05a11131628f, content=撰写文章题目有没有技巧？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:55 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113161, encodeId=14ea1113161e8, content=文章题目怎么写更好？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:55 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2200038, encodeId=9fea22000387d, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc86161054, createdName=ms3000001089264574, createdTime=Tue Apr 23 22:07:09 CST 2024, time=2024-04-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2195328, encodeId=27262195328a4, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：无投稿经验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=daa79231007, createdName=ms3000001661232973, createdTime=Mon Mar 25 21:56:28 CST 2024, time=2024-03-25, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2187957, encodeId=9517218e95705, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤 经验分享：编辑很nice，也很细心, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de166462153, createdName=ms9000001999156742, createdTime=Sun Feb 18 14:05:11 CST 2024, time=2024-02-18, status=1, ipAttribution=上海)]

2024-03-25 ms3000001661232973 来自广东省

审稿速度:1.0 | 投稿命中率:50.0
经验分享：无投稿经验

13 0

[GetPortalCommentsPageByObjectIdResponse(id=964326, encodeId=3f44964326fb, content=EClinicalMedicine has been accepted to the Science Citation Index Expanded and expects its first Journal Impact Factor in 2022. 这是该杂志官方首页上写的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=22e82567, createdName=dangjunsy, createdTime=Mon May 10 18:17:41 CST 2021, time=2021-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2157837, encodeId=5318215e8377a, content=2, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93bb8315605, createdName=ms1000000667415119, createdTime=Fri Sep 15 14:42:32 CST 2023, time=2023-09-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=580620, encodeId=2dd658062063, content=审稿速度:2.0 | 投稿命中率:75.0 经验分享：这个杂志是柳叶刀旗下的，与EBioMedicine对应，临床类各科文章皆收录，属于大而全的，所以取名为EClinicalMedicine，定位应该是承接被Lancet主刊和子刊退稿或拒稿的文章。未来应该与EBioMedicine差不多，在5分左右。就象Nature旗下的Nature Communication和Sci Rep一样，综合类期刊。不过，相对而言文章更好发表哦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=619, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Thu Nov 28 12:06:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205559, encodeId=1f75120555959, content=有同行如果有web of science的access可以精确预估一下今年的影响因子，2019+2020文章在2021年的引用次数/2019+2020文章数量，网站上的累计引用不准确, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=499, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66412075254, createdName=1881f0fc47m, createdTime=Thu Mar 24 13:43:20 CST 2022, time=2022-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201089, encodeId=8d88120108906, content=为什么最近的很多帖子都被删掉了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=355, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=22e82567, createdName=dangjunsy, createdTime=Wed Mar 09 23:10:55 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113162, encodeId=d05a11131628f, content=撰写文章题目有没有技巧？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:55 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1113161, encodeId=14ea1113161e8, content=文章题目怎么写更好？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:55 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2200038, encodeId=9fea22000387d, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dc86161054, createdName=ms3000001089264574, createdTime=Tue Apr 23 22:07:09 CST 2024, time=2024-04-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2195328, encodeId=27262195328a4, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：无投稿经验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=daa79231007, createdName=ms3000001661232973, createdTime=Mon Mar 25 21:56:28 CST 2024, time=2024-03-25, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2187957, encodeId=9517218e95705, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤 经验分享：编辑很nice，也很细心, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de166462153, createdName=ms9000001999156742, createdTime=Sun Feb 18 14:05:11 CST 2024, time=2024-02-18, status=1, ipAttribution=上海)]

2024-02-18 ms9000001999156742 来自上海

审稿速度:2.0 | 投稿命中率:95.0
偏重的研究方向：肿瘤
经验分享：编辑很nice，也很细心

46 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务